IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on ... [+] October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesWe believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. T ...

Johnson & Johnson (JNJ) announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), harboring susceptible FGFR3 genetic alterations.The drug has been approved for UC patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.UC is the most common type of bladder cancer. Europe has the highest rate of b ...

patpitchaya/iStock via Getty Images JNJ stock: buy rating reiterated It was about three months ago that I last analyzed Johnson & Johnson (NYSE:JNJ) stock. As the following screenshot shows, my last article was titled "Johnson & Johnson: Market Will Regret The Overreaction" and rated the stock as a buy. The article argued that recent price corrections were an overreaction to the temporary issues the stock has been facing such as the talc-related bankruptcy filings and the Stelara patent expiration. Quote: T ...

This leading pharmaceutical stock is flying under the radar right now.Eli Lilly (LLY 0.21%) is hogging the headlines as its market capitalization marches toward $1 trillion. But even as the market continues to evaluate the growing demand for anti-obesity drugs and bids up businesses in the weight-loss space, it could be ignoring other businesses in the pharma industry. As a result, quite a few pharmaceutical stocks are currently flying under the market's radar, and investors could be looking at solid opport ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $161.43, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.57%.Shares of the world's biggest maker of health care products witnessed a gain of 5.13% over the previous month, beating the performance of the Medical sector with its gain of 4.9% and the S&P 500's gain of 1.77%.Market par ...

文章核心观点 - 强生公司(JNJ)宣布以6亿美元的初始现金支付收购私营医疗设备公司V-Wave Ltd [1][2][3] - 此次收购旨在为强生公司医疗设备业务增添V-Wave的创新治疗设备Ventura Interatrial Shunt(IAS),这是一种用于治疗心力衰竭的微创设备 [2][3] - 此次交易预计将在2024年对强生公司的调整后每股收益产生24美分的摊薄,2025年为6美分的摊薄 [3] - 此次收购有助于强化强生公司医疗设备业务在心血管疾病领域的地位,并为该业务带来显著的增长潜力 [5][6][7] 根据相关目录分别进行总结 交易概况 - 强生公司以6亿美元的初始现金支付收购V-Wave公司 [1][3] - 此次交易还包括最高约11亿美元的潜在监管和商业里程碑付款 [3] - 交易预计将在2024年底前完成,需满足惯常的交割条件 [4] 收购动机和战略意义 - 此次收购有助于强生公司医疗设备业务在心血管疾病领域的地位,并为该业务带来显著的增长潜力 [5] - V-Wave公司开发的Ventura Interatrial Shunt(IAS)设备是一种用于治疗心力衰竭的创新微创设备 [2] - 美国每年约有80万名患者患有心力衰竭,此次收购为强生公司带来了巨大的市场机会 [5] 强生公司医疗设备业务发展情况 - 强生公司近年来通过多项收购交易不断丰富医疗设备业务组合,提升在心血管疾病领域的地位 [6][7] - 2022年收购Abiomed公司,使医疗设备业务拥有12个超过10亿美元年销售额的业务平台 [7] - 2024年上半年,医疗设备业务实现销售150.8亿美元,同比增长3.3%,经营性增长5.4% [7] - 强生公司预计2024年医疗设备业务将实现6%的增长 [7]

Johnson & Johnson (JNJ) announced that the FDA approved the combination of its intravenously administered EFGR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitor Lazcluze (lazertinib) as a chemotherapy-free treatment for a type of lung cancer.Following the FDA decision, Rybrevant combined with Lazcluze is approved as a first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutation ...

文章核心观点 - 强生公司获得FDA批准推出一种新的肺癌化疗免疫联合疗法,该疗法在临床试验中相比现有标准疗法可将疾病进展或死亡风险降低30% [1][3] - 强生公司以17亿美元收购私营公司V-Wave,以拓展其心血管健康业务 [5][6][7] 根据相关目录分别进行总结 肺癌新疗法 - FDA批准强生公司推出Rybrevant和Lazcluze两药联合用于治疗某些类型肺癌,这是首个优于现有标准疗法的化疗免疫联合疗法 [3] - 该疗法在临床试验中相比现有标准疗法可将疾病进展或死亡风险降低30% [3] - 这一里程碑性进展为患者及其家人带来了全新的治疗方式 [4] 心血管健康业务拓展 - 强生公司以17亿美元收购私营公司V-Wave,以拓展其心血管健康业务 [5][6] - 这是强生公司今年在心血管领域进行的又一次并购 [7]

RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinibFollowing Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of responseRARITAN, N.J., Aug. 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration ( ...

文章核心观点 - 公司第二季度收益和销售额超出预期,但由于并购成本导致每股收益指引下调 [3][4] - 公司创新药业务和医疗器械业务销售均有增长,但医疗器械业务增速低于预期 [8][22][26][27] - 公司维持全年收入指引,但下调了每股收益指引,主要由于并购带来的融资成本 [29][32][33] 关于创新药业务 - 创新药业务销售增长5.5%,主要得益于Darzalex、Stelara、Tremfya等主要产品的强劲表现 [8][9][11][12][14][15] - 新药Carvykti、Tecvayli和Spravato也为业务增长做出贡献 [16] - 部分产品如Imbruvica和Zytiga受到竞争压力影响销售下滑 [13][19] - 公司预计创新药业务将连续第13年实现高于市场的增长 [21] 关于医疗器械业务 - 医疗器械业务销售增长2.2%,低于预期,主要受到中国市场VBP政策和竞争压力的影响 [22][25][26] - 心血管和骨科业务表现较好,但外科和视觉业务受到压力 [26] - 公司预计下半年医疗器械业务增速将加快,全年增速预计接近6% [27][28] 财务指引 - 公司维持全年收入指引,但下调了每股收益指引,主要由于并购带来的融资成本 [29][32][33] - 其他收入和利息收入指引也有所下调 [36] - 分析师对公司未来业绩预期有所下调 [37][40]